Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 20 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners, LLC, a life sciences focused venture capital firm. Prior to ETP he was a vice president and portfolio manager at T. Rowe Price, where his responsibilities included managing $2 billion of mutual fund and institutional client portfolios. Some of Mr. Snider’s past directorships include Alpha Innotech, Molecular Transfer, and Atto Biosciences, and he currently serves on the boards of Astero Bio, BioInformatics, and the MdBio Foundation. He has made more than 30 growth capital investments while at BroadOak, and looks forward to making 30 more.

Bill holds the Chartered Financial Analyst accreditation, and graduated without honors, twice, from the Wharton School at the University of Pennsylvania: once to earn a B.S.E. in Finance, and later, an M.B.A. His golf game hasn’t improved in the last 20 years, and he suspects he might be better at tennis. Bill has been dedicated to youth rowing since his daughter entered high school; he discovered his passion for crew when he walked onto the team at Penn.

Dr. Shahram Hejazi is a medical device/life science executive with general management experience in both early-stage ventures and large global companies. As a Venture Partner with BioAdvance, he is responsible for investments in device, diagnostics and imaging field. Previously, Dr. Hejazi was the President of Kodak’s life science division (now called Carestream Molecular Imaging), where he had global responsibility for R&D, manufacturing, operations, sales, marketing and service. Before Kodak, he was the CEO of Zargis Medical Corporation (an early-stage medical device company that spun off from Siemens), where he led the company’s efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval and product launch. Prior to Zargis, Dr. Hejazi was the Head of the Strategic Business Development group at Siemens, responsible for identifying early-stage growth/investment opportunities and new business development in the medical field.

Dr. Keegan has more than 30 years of experience in life science businesses. As CEO at ForteBio, Inc., he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45%, and exited the company through its sale to Pall Corporation, returning $160M to investors. During his 9-year tenure at Molecular Devices Corporation, Dr. Keegan grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company, where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Board of Directors of Arrayjet LTD, Bio-Techne (NASDAQ:TECH), Carterra, Interpace Diagnostics (NASDAQ:IDXG), Labcyte as Chairman and Nanomedical Diagnostics as Executive Chairman. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

Souvignier conducts the scientific and business analysis of early-stage biomedical investment opportunities for RCT and also manages a portfolio of projects and investments for RCT. His areas of focus at RCT include oncology, pain, central nervous system disorders, diabetes and metabolic disease.

Robert has over 25 years of experience in life science instrumentation and product development. Before Halo, Robert was General Manager of Pall ForteBio responsible for growing the company with YOY growth of over 25% every year for four years. Robert was also the Senior VP of Instrumentation R&D at Pall Corporation and a corporate M&A member, helping acquire a variety of companies into Pall’s numerous markets. Before Pall, Robert was VP of Product Development and Operations for ForteBio from 2007 to 2012 where he helped exit the company to Pall Corporation for over $160M. Before that, Robert was at Molecular Devices Corporation, where he was Vice President of Product Development, being on the executive team that helped the $615M acquisition by MDS. Previously he was at Axon Instruments, Inc. for 13 years, as Vice President of Software Engineering, helping be the first private company to IPO on the Australian stock market, and then helped with the $140 million acquisition by Molecular Devices. Robert received a BA in Computer and Information Sciences and Mathematics from Drew University, NJ and an MS in Computer and Information Sciences from the University of Oregon.